Today's Reuters Health News Headlines - Yahoo! News:
|
|
Former Olympus CEO Woodford says ready to return: report
Thu,24 Nov 2011 05:09 PM PST
Reuters - TOKYO (Reuters) - Former Olympus Corp CEO Michael Woodford said he is ready to return to the company but added the decision is up to shareholders, Kyodo news agency reported on Friday. Woodford arrived at Olympus headquarters in Tokyo earlier on Friday in a boardroom showdown a month after he was fired and went public with suspicions about the company's past M&A deals. (Reporting by Isabel Reynolds; Editing by Edwina Gibbs) Full Story | Top |
Cost agency backs BMS, Pfizer anti-clot drug
Thu,24 Nov 2011 04:06 PM PST
Reuters - LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog has recommended Bristol-Myers Squibb and Pfizer's new pill Eliquis for preventing blood clots after hip and knee surgery, following a fast-track review. The final draft guidance from the National Institute for Health and Clinical Excellence (NICE) comes just six months after Eliquis was licensed in Europe, marking an unusually rapid decision by the agency that determines which drugs are paid for on the state health service. ... Full Story | Top |
Ex-Olympus CEO Woodford: No surprise if crime link to scandal
Thu,24 Nov 2011 03:41 PM PST
Reuters - TOKYO (Reuters) - Former Olympus Corp CEO Michael Woodford said on Thursday he would not be surprised if there was "some criminality involved" in an accounting scandal at the company, as speculation persists of a link between dubious M&A deals and organized crime. Woodford also told an audience of business executives in Tokyo that he had a "dream team" at Olympus he could employ to run the company if he returned as chief executive. Olympus fired Woodford as CEO on October 14, saying he did not understand Japanese culture. Woodford said his dismissal was due to questioning dubious M&A payments. ... Full Story | Top |
Gaddafi son needs surgery on gangrenous fingers: doctor
Thu,24 Nov 2011 01:48 PM PST
Reuters -  ZINTAN/TRIPOLI, Libya (Reuters) - Muammar Gaddafi's son Saif al-Islam needs surgery to remove gangrenous flesh from a severed thumb and finger which if not treated could make him seriously ill, a doctor who examined him told Reuters on Thursday. Saif al-Islam has been nursing injuries to his right hand which he says were sustained during a NATO airstrike weeks ago. No further details have been available on the state of his heavily bandaged thumb, index and middle fingers. ...
Full Story | Top |
Migraines may raise depression risk: study
Thu,24 Nov 2011 12:48 PM PST
Reuters - NEW YORK (Reuters Health) - People who get painful migraine headaches may be at a higher risk for developing clinical depression, suggests a new study from Canada. The research, published in the journal Headache, also hints that the relationship may go both ways, and people with clinical depression could have a higher risk of developing migraines, but that finding could have been due to chance, the researchers say. ... Full Story | Top |
Moderate drinking tied to lower diabetes risk
Thu,24 Nov 2011 12:47 PM PST
Reuters -  By Linda Thrasybule NEW YORK (Reuters Health) - Middle aged women who eat a lot of refined carbs might offset their risk of type 2 diabetes by drinking a moderate amount of alcohol, a new study suggests. Following more than 80,000 women over 26 years, researchers found that those who ate a diet high in refined carbohydrates, such as white bread, potatoes and sugary drinks, had a 30 percent lower risk of developing diabetes than women with similar eating habits who didn't drink alcohol. ...
Full Story | Top |
Aspirin not worth risks for healthy women: study
Thu,24 Nov 2011 12:45 PM PST
Reuters - NEW YORK (Reuters Health) - Aspirin is a bad bargain for healthy women trying to stave off heart attacks or strokes, although it's commonly used for that purpose, according to Dutch researchers. In a new report, they say 50 women will need to take the medication for 10 years for just one to be helped -- and that's assuming they are at high risk to begin with. "There are very few women who actually benefit," said Dr. Jannick Dorresteijn of University Medical Center Utrecht in The Netherlands. ... Full Story | Top |
UK switches to Merck's Gardasil for HPV vaccination
Thu,24 Nov 2011 12:38 PM PST
Reuters - LONDON (Reuters) - Britain is to stop using GlaxoSmithKline's cervical cancer vaccine Cervarix from next September and will instead offer girls Merck & Co's rival product Gardasil. The move underscores Gardasil's lead in a $1 billion-plus worldwide market for vaccines that protect against the sexually transmitted human papillomavirus (HPV), which can cause cervical cancer. The health ministry said Thursday the decision followed a competitive tendering exercise. ... Full Story | Top |
"Welcome to hell": Egypt medics struggle in Tahrir clinic
Wed,23 Nov 2011 09:50 PM PST
Reuters - CAIRO (Reuters) - Before doctors can treat the steady stream of casualties brought to their makeshift hospital in Tahrir Square, they must first treat themselves for the effects of the tear gas which fills the air. Providing medical support to the youths confronting the Egyptian security forces just down the road is a dangerous business: three of the volunteer doctors have been killed in the violence, said Tareq Salem, one of the doctors at work in the clinic late on Wednesday. ... Full Story | Top |
Olympus shares jump more than 11 percent, delisting fears fade
Wed,23 Nov 2011 04:51 PM PST
Reuters -  TOKYO (Reuters) - Embattled Olympus Corp jumped more than 11 percent on Thursday for its third day of gains, with investors appearing less worried that the stock would be delisted by the Tokyo Stock Exchange. The scandal-hit company said on Monday a third-party panel investigating an accounting scandal found no evidence of funds from M&A deals flowing to organized crime syndicates. Olympus was trading 8 percent higher at 941 yen after earlier jumping more than 11 percent in morning trade. The stock was the heaviest-traded share by turnover on the main board. ...
Full Story | Top |
Transcept's night-waking cure gets FDA nod
Wed,23 Nov 2011 04:27 PM PST
Reuters - (Reuters) - A first-of-its-kind drug for patients who face difficulty in going back to sleep after abruptly waking up in the middle of the night is expected to hit market next year, with the U.S. approval Wednesday of Transcept Pharmaceuticals' Intermezzo. Transcept, which specializes in developing therapies in the field of neuroscience, said its marketing partner Purdue Pharmaceutical Ltd had until December 8 to notify if it would proceed with the commercialization. ... Full Story | Top |
Novartis eye drug suffers fresh rebuff in Britain
Wed,23 Nov 2011 04:23 PM PST
Reuters - LONDON (Reuters) - Novartis's costly eye drug Lucentis has been rejected for another new use by NICE, following a similar setback in July. The National Institute for Health and Clinical Excellence (NICE) said on Thursday its preliminary recommendation was against using Lucentis for visual impairment caused by macular oedema secondary to central or branch retinal vein occlusion. NICE, which decides if particular treatments should be used on the state-run health service, had previously rejected Lucentis for diabetic macular oedema. ... Full Story | Top |
Novartis eye drug suffers fresh rebuff in Britain
Wed,23 Nov 2011 04:02 PM PST
Reuters - LONDON (Reuters) - Novartis's costly eye drug Lucentis has been rejected for another new use by Britain's health cost-effectiveness watchdog NICE, following a similar setback in July. The National Institute for Health and Clinical Excellence (NICE) said on Thursday its preliminary recommendation was against using Lucentis for visual impairment caused by macular oedema secondary to central or branch retinal vein occlusion. NICE, which decides if particular treatments should be used on the state-run health service, had previously rejected Lucentis for diabetic macular oedema. ... Full Story | Top |
Ontario cuts growth targets, says budget on track
Wed,23 Nov 2011 03:49 PM PST
Reuters -  TORONTO (Reuters) - The Ontario government cut its growth, revenue and reserve targets on Wednesday, but said it was still on track to balance the budget in six years, without lowering total program spending or raising taxes. In its fall economic statement, the government of Canada's most populous province said the timetable for eliminating its 2011-12 deficit of C$16 billion ($15.2 billion) by 2017-18 remains intact, as do medium-term targets, despite pressures from economic turmoil in the United States and Europe. ...
Full Story | Top |
Pozen sells migraine drug's U.S. rights to Canada fund
Wed,23 Nov 2011 03:23 PM PST
Reuters - (Reuters) - Pozen Inc sold its right to receive American royalties from its migraine drug to Canada's national pension fund, sending the pharmaceutical company's shares up as much as 32 percent in extended trade. The company received $75 million for the deal and would get a fifth of any royalties received by the fund, CPPIB Credit Investments, from April 1, 2018, Pozen said in a filing. GlaxoSmithKline holds the license to develop and market Trexmet in the United States, and Pozen has the right to develop and market a lower dose of the drug outside the country. ... Full Story | Top |
| |
|
No comments:
Post a Comment